Spotlight
Specialty
Partners
CME/CE
The Potential Impact of Tislelizumab on First-Line ESCC Treatment
Drs Saba and Yoon reflect on how the potential FDA approval and availability of tislelizumab might change first-line ESCC treatment paradigms in the future.
EP: 1.Trends in ESCC Incidence and Observations from Clinical Practice
EP: 2.Approaches to Biomarker Testing for ESCC
EP: 3.The Impact of Biomarker Results on Prognosis and Treatment Decision-Making
EP: 4.First-Line Options for Advanced/Metastatic Disease
EP: 5.Insights on ESCC First-Line Treatment Selection
EP: 6.RATIONALE-306 Data on Tislelizumab in ESCC
Now Viewing
EP: 7.The Potential Impact of Tislelizumab on First-Line ESCC Treatment
EP: 8.Other Emerging Regimens in ESCC and Lessons from Other Squamous Cell Cancers
EP: 9.A Look Towards the Future of ESCC
Related Videos
